Agency Information Collection Activities: Proposed Collection; Comment Request, 18307-18308 [2017-07764]

Download as PDF Federal Register / Vol. 82, No. 73 / Tuesday, April 18, 2017 / Notices Translational Sciences (NCATS) and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Submissions may be sent electronically to DK-IDG-Phase2-RFI@ mail.nih.gov or by mail to Dr. Karlie Sharma, National Center for Advancing Translational Sciences, National Institutes of Health, 6701 Democracy Blvd., Suite 900, Bethesda, MD 20892. ADDRESSES: FOR FURTHER INFORMATION CONTACT: Questions about this request for information should be directed to Dr. Karlie Sharma, National Center for Advancing Translational Sciences, National Institutes of Health, 6701 Democracy Blvd., Suite 900, Bethesda, MD 20892, DK-IDG-Phase2-RFI@ mail.nih.gov, 301–451–4965. Out of the nearly 30,000 genes in the human genome, approximately 3,000 genes are estimated to be part of the druggable genome—the subset of genes expressing proteins with the ability to bind druglike molecules. Yet, only about ten percent of druggable proteins are targeted by Food and Drug Administration (FDA)-approved drugs. Many proteins that comprise the druggable genome are members of the Gprotein coupled receptor (GPCR), ion channel, and kinase families. A significant number of proteins within these classes are understudied and are the focus of the data and resource generation initiative of the IDG Program. SUPPLEMENTARY INFORMATION: sradovich on DSK3GMQ082PROD with NOTICES 1. Goals and Requirements The IDG Program was originally funded as a three-year pilot program in 2014 with two overarching goals: (1) Integrate information about understudied druggable proteins from disparate sources into a single informatics site and (2) foster technology development to enable the determination of function and therapeutic potential of understudied druggable proteins. Having successfully achieved these goals, the IDG Program is currently transitioning to a new implementation phase intended to: • Expand the informatics tools developed in the pilot phase to include additional data and allow users to access, analyze, and visualize a wide range of information on sets of proteins. • Facilitate the elucidation of the function of understudied proteins from the three key druggable protein families (GPCR, ion channels, and kinases) by generating new reagents and new data. • Disseminate the IDG-generated resources and data to the greater scientific community. VerDate Sep<11>2014 16:55 Apr 17, 2017 Jkt 241001 2. Information Requested NIH is seeking input from national and international experts and interested members of the public that includes, but is not limited to, the following areas: • Resources that an outside organization (biotechnology or pharmaceutical company; non-profit organization; academic institution and national/international consortia) might be willing to share with the IDG Program and may: Æ Strategize development of chemical probes against proteins drawn from the IDG focused list Æ develop assays and platforms that can help to answer questions about understudied protein function Æ identify reagents that may be useful in annotation efforts Æ provide data or knowledge on any understudied protein • Potential resources of the IDG Program that are of interest to an outside organization of the broader biomedical research community including: Æ Sharable databases of relevant subsets of data on understudied proteins Æ data analysis and query tools Æ links between protein target and disease pathologies Æ new methods of analysis to accelerate collection of data This RFI is for planning purposes only and should not be construed as a solicitation for applications or proposals, or as an obligation in any way on the part of the United States Federal government. The Federal government will not pay for the preparation of any information submitted or for the government’s use. Additionally, the government cannot guarantee the confidentiality of the information provided. Dated: April 12, 2017. Christopher P. Austin, Director, NCATS. Griffin P. Rodgers, Director, NIDDK, Illuminating the Druggable Genome Program, National Center for Advancing Translational Sciences, National Institute of Diabetes and Digestive and Kidney Diseases. [FR Doc. 2017–07795 Filed 4–17–17; 8:45 am] BILLING CODE 4140–01–P PO 00000 Frm 00031 Fmt 4703 Sfmt 4703 18307 DEPARTMENT OF HEALTH AND HUMAN SERVCES Substance Abuse and Mental Health Services Administration Agency Information Collection Activities: Proposed Collection; Comment Request In compliance with Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995 concerning opportunity for public comment on proposed collections of information, the Substance Abuse and Mental Health Services Administration (SAMHSA) will publish periodic summaries of proposed projects. To request more information on the proposed project or to obtain a copy of the information collection plans, call the SAMHSA Reports Clearance Officer at (240) 276– 1243. Comments are invited on: (a) Whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency’s estimate of the burden of the proposed collection of information; (c) ways to enhance the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology. Proposed Project: Strategic Prevention Framework for Prescription Drugs (SPF-Rx)—New The Substance Abuse and Mental Health Services Administration (SAMHSA)’s Center for Substance Abuse Prevention (CSAP) aims to conduct a cross-site evaluation of the Strategic Prevention Framework for Prescription Drugs (SPF-Rx) program. The SPF-Rx program is designed to address nonmedical use of prescription drugs (as well as opioid overdoses) by raising awareness about the dangers of sharing medications. and by working with pharmaceutical and medical communities. The SPF-Rx program aims to promote collaboration between states/ tribes and pharmaceutical and medical communities to understand the risks of overprescribing to youth ages 12–17 and adults 18 years of age and older. The program also aims to enhance capacity for, and access to, Prescription Drug Monitoring Program (PDMP) data for prevention purposes. The SPF-Rx program aims to address SAMHSA’s priorities on prevention and E:\FR\FM\18APN1.SGM 18APN1 18308 Federal Register / Vol. 82, No. 73 / Tuesday, April 18, 2017 / Notices reduction of prescription drug and illicit opioid misuse and abuse. Its indicators of success are reductions in opioid overdoses and the incorporation of PDMP data into needs assessments and strategic plans. Data collected through the tools described in this statement will be used for the national cross-site evaluation of SAMHSA’s SPF-Rx program. This package covers continued data collection through 2020, as the evaluation is expected to continue through at least that time; however, the Program Evaluation for Prevention Contract (PEP–C) is scheduled to conduct a national cross-site evaluation of SPF-Rx through September 2018. The PEP–C team will systematically collect and maintain an Annual Implementation Instrument (AII) and outcomes data submitted by SPF-Rx grantees through the online PEP–C Management Reporting Tool (MRT). SAMHSA is requesting approval for data collection for the SPF-Rx cross-site evaluation with the following four instruments: • Substitute Data Source Request to allow grantees to request permission from SAMHSA to use ‘‘substitute measures’’ for their outcomes data—that is, measures that differ from a list of preapproved outcomes measures. • Annual Implementation Instrument to collect data completed by grantees and subrecipient community PDs. Data collected from the survey will be used to monitor subrecipient and state, tribal entity, or jurisdiction performance, and to evaluate the effectiveness of the SPFRx program across states, tribal entities, and jurisdictions. • Grantee Interview to collect semistructured telephone interview data to gather more in-depth information on organizational infrastructure, use of PDMP data. • Evaluation Plan to allow grantees to outline their local evaluation plan. This section should include goals and objectives, performance measures, a data analysis plan, and reporting plan. • Grantee Interview to obtain the perspective of the implementing Project Directors (PDs) or their staff on important topics, including infrastructure and capacity, collaboration, leveraging funding and resources, criteria and use of evidenceinformed interventions, monitoring and evaluation, collaboration, challenges, and health disparities. Information from these interviews will help inform SPFRx cross-site evaluation reports and will help identify lessons learned and success stories from grantees’ SPF-Rx programs. • Grantee- and Community-Level Outcomes Modules to collect data on key SPF-Rx program outcomes, including opioid misuse and abuse, opioid overdoses, and opioid prescribing patterns. Grantees will provide outcomes data at the grantee level for their state, tribal area, or jurisdiction, as well as at the community level for each of their subrecipient communities. ANNUALIZED DATA COLLECTION BURDEN Number of respondents Instrument Grantee-Level Outcomes Module ........................................ Community-Level Outcomes Module ................................... Substitute Data Request Form ............................................ Annual Implementation Instrument ...................................... Grantee-Level Interview ....................................................... Evaluation Plan .................................................................... Overall Total ................................................................. 25 25 3.67 100 17 25 170.67 Responses per respondent Total number of responses 1 1 1 1 1 1 ........................ 25 25 3.67 100 17 25 170.67 Hours per response 3 3 1 2.3 1.5 8 ........................ Total burden hours 75 75 3.67 230 25.5 200 609.17 Note: Annualized Data Collection Burden captures the average number of respondents and responses, burden hours, and respondent cost over the 3 years (FY2018–FY2020). Send comments to Summer King, SAMHSA Reports Clearance Officer, 5600 Fishers Lane, Room 15E57–B, Rockville, Maryland 20857, OR email a copy to summer.king@samhsa.hhs.gov. Written comments should be received by June 19, 2017. Summer King, Statistician. [FR Doc. 2017–07764 Filed 4–17–17; 8:45 am] BILLING CODE 4162–20–P DEPARTMENT OF THE INTERIOR Bureau of Land Management [LLCAN01000 L10200000.XZ0000 17X LXSIOVHD0000] Notice of Public Meeting: Northern California District Resource Advisory Council Bureau of Land Management, Interior. ACTION: Notice. AGENCY: In accordance with the Federal Land Policy and Management Act of 1976, and the Federal Advisory Committee Act of 1972, the U.S. Department of the Interior, Bureau of Land Management’s (BLM) Northern California District Resource Advisory Council (RAC) will meet as indicated below. sradovich on DSK3GMQ082PROD with NOTICES SUMMARY: The meeting will be held on Wednesday, April 26, 2017, from 10 DATES: VerDate Sep<11>2014 16:55 Apr 17, 2017 Jkt 241001 PO 00000 Frm 00032 Fmt 4703 Sfmt 4703 a.m. to 4 p.m. The meeting is open to the public. Public comments will be accepted at 11 a.m. to noon. ADDRESSES: The meeting will be held in the conference room of the Bureau of Land Management Northern California District Office, 6640 Lockheed Drive, Redding, CA 96002. Those unable to attend can participate by teleconference. The toll-free telephone number is (888) 282–0374, and the passcode is 50716. Written comments can be sent to the district office at the above address. FOR FURTHER INFORMATION CONTACT: BLM Northern California District Manager, Alan Bittner, (530) 224–2160; or Public Affairs Officer, Joseph J. Fontana, (530) 252–5332. Persons who use a telecommunications device for the deaf may call the Federal Relay Service at 800–877–8339, to contact the above individuals during normal business hours. The Service is available 24 hours a day, 7 days a week, to leave a message or question with the above individual. E:\FR\FM\18APN1.SGM 18APN1

Agencies

[Federal Register Volume 82, Number 73 (Tuesday, April 18, 2017)]
[Notices]
[Pages 18307-18308]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-07764]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVCES

Substance Abuse and Mental Health Services Administration


Agency Information Collection Activities: Proposed Collection; 
Comment Request

    In compliance with Section 3506(c)(2)(A) of the Paperwork Reduction 
Act of 1995 concerning opportunity for public comment on proposed 
collections of information, the Substance Abuse and Mental Health 
Services Administration (SAMHSA) will publish periodic summaries of 
proposed projects. To request more information on the proposed project 
or to obtain a copy of the information collection plans, call the 
SAMHSA Reports Clearance Officer at (240) 276-1243.
    Comments are invited on: (a) Whether the proposed collection of 
information is necessary for the proper performance of the functions of 
the agency, including whether the information shall have practical 
utility; (b) the accuracy of the agency's estimate of the burden of the 
proposed collection of information; (c) ways to enhance the quality, 
utility, and clarity of the information to be collected; and (d) ways 
to minimize the burden of the collection of information on respondents, 
including through the use of automated collection techniques or other 
forms of information technology.

Proposed Project: Strategic Prevention Framework for Prescription Drugs 
(SPF-Rx)--New

    The Substance Abuse and Mental Health Services Administration 
(SAMHSA)'s Center for Substance Abuse Prevention (CSAP) aims to conduct 
a cross-site evaluation of the Strategic Prevention Framework for 
Prescription Drugs (SPF-Rx) program. The SPF-Rx program is designed to 
address nonmedical use of prescription drugs (as well as opioid 
overdoses) by raising awareness about the dangers of sharing 
medications. and by working with pharmaceutical and medical 
communities. The SPF-Rx program aims to promote collaboration between 
states/tribes and pharmaceutical and medical communities to understand 
the risks of overprescribing to youth ages 12-17 and adults 18 years of 
age and older. The program also aims to enhance capacity for, and 
access to, Prescription Drug Monitoring Program (PDMP) data for 
prevention purposes.
    The SPF-Rx program aims to address SAMHSA's priorities on 
prevention and

[[Page 18308]]

reduction of prescription drug and illicit opioid misuse and abuse. Its 
indicators of success are reductions in opioid overdoses and the 
incorporation of PDMP data into needs assessments and strategic plans. 
Data collected through the tools described in this statement will be 
used for the national cross-site evaluation of SAMHSA's SPF-Rx program. 
This package covers continued data collection through 2020, as the 
evaluation is expected to continue through at least that time; however, 
the Program Evaluation for Prevention Contract (PEP-C) is scheduled to 
conduct a national cross-site evaluation of SPF-Rx through September 
2018. The PEP-C team will systematically collect and maintain an Annual 
Implementation Instrument (AII) and outcomes data submitted by SPF-Rx 
grantees through the online PEP-C Management Reporting Tool (MRT).
    SAMHSA is requesting approval for data collection for the SPF-Rx 
cross-site evaluation with the following four instruments:
     Grantee Interview to obtain the perspective of the 
implementing Project Directors (PDs) or their staff on important 
topics, including infrastructure and capacity, collaboration, 
leveraging funding and resources, criteria and use of evidence-informed 
interventions, monitoring and evaluation, collaboration, challenges, 
and health disparities. Information from these interviews will help 
inform SPF-Rx cross-site evaluation reports and will help identify 
lessons learned and success stories from grantees' SPF-Rx programs.
     Grantee- and Community-Level Outcomes Modules to collect 
data on key SPF-Rx program outcomes, including opioid misuse and abuse, 
opioid overdoses, and opioid prescribing patterns. Grantees will 
provide outcomes data at the grantee level for their state, tribal 
area, or jurisdiction, as well as at the community level for each of 
their subrecipient communities.
     Substitute Data Source Request to allow grantees to 
request permission from SAMHSA to use ``substitute measures'' for their 
outcomes data--that is, measures that differ from a list of preapproved 
outcomes measures.
     Annual Implementation Instrument to collect data completed 
by grantees and subrecipient community PDs. Data collected from the 
survey will be used to monitor subrecipient and state, tribal entity, 
or jurisdiction performance, and to evaluate the effectiveness of the 
SPF-Rx program across states, tribal entities, and jurisdictions.
     Grantee Interview to collect semistructured telephone 
interview data to gather more in-depth information on organizational 
infrastructure, use of PDMP data.
     Evaluation Plan to allow grantees to outline their local 
evaluation plan. This section should include goals and objectives, 
performance measures, a data analysis plan, and reporting plan.

                                        Annualized Data Collection Burden
----------------------------------------------------------------------------------------------------------------
                                     Number of     Responses per   Total number      Hours per     Total burden
           Instrument               respondents     respondent     of responses      response          hours
----------------------------------------------------------------------------------------------------------------
Grantee-Level Outcomes Module...              25               1              25               3              75
Community-Level Outcomes Module.              25               1              25               3              75
Substitute Data Request Form....            3.67               1            3.67               1            3.67
Annual Implementation Instrument             100               1             100             2.3             230
Grantee-Level Interview.........              17               1              17             1.5            25.5
Evaluation Plan.................              25               1              25               8             200
    Overall Total...............          170.67  ..............          170.67  ..............          609.17
----------------------------------------------------------------------------------------------------------------
Note: Annualized Data Collection Burden captures the average number of respondents and responses, burden hours,
  and respondent cost over the 3 years (FY2018-FY2020).

    Send comments to Summer King, SAMHSA Reports Clearance Officer, 
5600 Fishers Lane, Room 15E57-B, Rockville, Maryland 20857, OR email a 
copy to summer.king@samhsa.hhs.gov. Written comments should be received 
by June 19, 2017.

Summer King,
Statistician.
[FR Doc. 2017-07764 Filed 4-17-17; 8:45 am]
 BILLING CODE 4162-20-P